Data Safety Monitoring Board Guidance To Provide Rules For Halting Trials
This article was originally published in The Gray Sheet
FDA's draft guidance on data safety monitoring boards (DSMBs) will address when clinical trials should be stopped for safety or efficacy reasons.
You may also be interested in...
Clinical trial sponsors are limited in their ability to facilitate compliance with institutional review boards, even though investigators often lack thorough grounding in IRB policies, according to Medtronic Director of Clinical Affairs Barbara Westrum
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.